Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lymphomas
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lymphomas
    FDA Approves Romidepsin Injection for Previously Treated T-Cell Lymphoma - (DGNews)
    Immune Therapy Can Protect Against or Treat Later Lymphoma - (DGNews)
    TopAbstracts in Lymphomas 10/28/2009 - (DGNews)
    Non-Invasive Diagnostic Tool Can Differentiate Among Small Round Blue Tumours: Presented at AAP - (DGDispatch)
    FDA Approves Rasburicase for Management of Hyperuricemia in Patients With Haematologic Malignancies - (DGNews)

    News archive

     Recent webcasts/CME - Lymphomas

    Webcasts/CME archive

     Recent cases - Lymphomas
      Primary Central Nervous System Lymphoma Presenting as Bilateral Uveitis in an Immunocompetent HCV+ Patient: A Case Report
      Primary Malignant Lymphoma of the Ileum Presenting as Intussusception
      Challenging Complications of Treatment - Human Herpes Virus 6 Encephalitis and Pneumonitis in a Patient Undergoing Autologous Stem Cell Transplantation for Relapsed Hodgkin's Disease: A Case Report
      Isolated Hodgkin's Lymphoma of the Oesophagus: A Case Report
      Pulmonary Lymphoma Mimicking Metastases: A Case Report

      Cases archive
        




      my personal edition > lymphomas > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Rituximab Provides Effective Rescue Treatment for Patients With Refractory Immune Thrombocytopenia Purpura: Presented at NHL

      By Chris Berrie

      PRAGUE, CZECH REPUBLIC -- September 14, 2004 -- Rituximab represents a rescue treatment for patients with refractory immune thrombocytopenia purpura (ITP), according to a Spanish multicentre retrospective study presented here September 12th at The Role of Immunotherapy in NHL: Optimising Treatment Outcomes, sponsored by Roche.

      Clinical Investigator Jorge Gayoso, PhD, haematology department, Clinica Puerta de Hierro, Madrid, Spain, introduced the study on behalf of clinical chief and coordinator Jose Rafael Cabrera, MD, and the whole author group of this Multi-Institutional Retrospective Study. "In the present study, we have evaluated the effectiveness of rituximab in the treatment of refractory patients diagnostic for ITP," Dr. Gayoso said.

      The data were collected to March 2004 through completion of clinical characteristics and response questionnaires that were received from the physicians of 99 patients in 43 centres. Among the 92 evaluable patients, platelet counts were below 30x 106/L, median age at diagnosis was 54 years (range 4-98), and 56% were women. Overall, 55% had idiopathic ITP, 14% had ITP associated with B-cell chronic lymphocytic leukaemia, 9% had autoimmune disease, and 3% had lymphoma; 12% had a range of other diseases.

      Prior to rituximab administration, the patients received several treatment schemes, including corticosteroids (98%), intravenous immunoglobulin (88%) and cyclophosphamide (26%). Those that had received more than 3 lines of treatment (85%) were classified as heavily pretreated. Splenectomies had been performed on 52%.

      Median time from diagnosis to rituximab treatment was 31 months, and overall median platelet count before rituximab was 8x 106/L, with 66% having a platelet count below 10x 106/L. Almost all patients (87%) received the standard dosing of rituximab (4x 375 mg/m2/week), with 37% receiving it in combination with other treatments.

      Standard response criteria were defined according to platelet counts: complete >100x 106/L; partial, 50-100x 106/L; minimal 30-50x 106/L.

      The 55% overall response rate comprised 46% in complete response (CR) and 9% in partial response (PR), with 40% nonresponders. Dr. Gayoso noted that 40% of responders were seen in the first week of treatment, although maximum responses were achieved after a median of 5 weeks. The median platelet count at maximum response was 141x 106/L (P <.001, analysis of variance).

      The nonsplenectomised patients showed a significantly better response rate (CR+PR) than those who were splenectomised (68% vs 42%; P =.018), although this significance was lost in the maintained response rates (36% vs 33%). Heavily pretreated patients showed a worse response rate than the rest of patients (55% vs 77%, respectively; P =.012). However, no differences were seen between patients who had received rituximab alone and those with rituximab combinations, both for CR (44% vs 47%) and for maintained response (34% vs 36%). Similarly, age and gender did not affect the responses to rituximab.

      Overall, after median monitoring of 9 months, 32% of patients maintained their CR, which did not vary significantly according to the associated diseases (P =.88). Rituximab was also well tolerated, with 2 episodes of fever following infusion, and 2 reports of skin eruptions.

      "These results suggest that rituximab can be considered as a rescue treatment in patients with refractory ITP, with an excellent tolerance supplied," Dr. Gayoso concluded. However, he also stressed the need for further studies to establish the real role of rituximab in this setting.


      [Presentation title: Treatment of Refractory Immune Thrombocytopaenic Purpura With Rituximab. Abstract 548]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send